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1. Introduction 
The first cases of Acquired Immune Deficiency Syndrome (AIDS) were described in the 
United States in 19811. In Kenya, the first case was recognized in 19842 and since that time, 
Human Immunodeficiency Virus (HIV)/AIDS still remains a huge barrier to social and 
economic development. It is estimated that 33.4 million people worldwide were living with 
HIV by December 2008. During 2008 more than two and a half million adults and children 
became infected with HIV. Sub-Saharan Africa remains the epicenter3. Recent data show 
HIV prevalence in Kenya of 7.4%, resulting in 1.4 million Kenyans living with HIV. An 
estimated 190,000 HIV-infected Kenyans receive Antiretroviral therapy (ART), representing 
44% of those in need of treatment4. Access to ART in Kenya has significantly increased since 
the start of the World Health Organization (WHO) 3 by 5 initiative. The Kenya AIDS 
indicator survey of 2007 showed that of the estimated 392,000 Kenyan adults in need of 
ART, 138,000 (35%) had received the treatment by September 20074.  
Human immunodeficiency virus is a highly variable virus due to rapid mutation. This results 
in many different strains of HIV, even within the body of a single infected person. There are 
two types of HIV: HIV-1 and HIV-2. Both types are transmitted by sexual contact, through 
blood, and from mother to child, and they cause clinically indistinguishable AIDS. However, 
HIV-2 is less easily transmitted, and the period between initial infection and illness is longer in 
the case of HIV-2. Worldwide, the predominant virus is HIV-1. The relatively uncommon HIV-
2 type is concentrated in West Africa and is rarely found elsewhere5. 
The strains of HIV-1 are classified into three groups: the "major" group M, the "outlier" 
group O and the "new" group N. These three groups represent three separate introductions 
of SIV into humans. Members of HIV-1 group O have been recovered from individuals 
living in Cameroon, Gabon, and Equatorial Guinea with the genomes sharing less than 50% 
identity with group M viruses6. The group N HIV-1 strains have been identified in infected 
Cameroonians7. In 2009, a newly-analyzed HIV sequence was reported to have greater 
similarity to a Simian Immunodeficiency Virus (SIV) recently discovered in wild gorillas 
(SIVgor) than to SIVs from chimpanzees (SIVcpz). The virus had been isolated from a 
Cameroonian woman residing in France who was diagnosed with HIV-1 infection in 2004. 
The scientists reporting this sequence placed it in a proposed Group P "pending the 
identification of further human cases8. 
More than 90% of HIV-1 infections belong to HIV-1 group M. Within group M there are nine 
genetically distinct subtypes (or clades) of HIV-1. These are subtypes A, B, C, D, F, G, H, J 
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and K9. The HIV-1 population present within an individual can vary from 6% to 10% in 
nucleotide sequences. Human immunodeficiency virus type 1 isolates within a clade may 
exhibit nucleotide distances of 15% in gag and up to 30% in gp 120 coding sequences. One 
obvious consequence of the genetic diversity of HIV-1 is the potential impact on the efficacy 
of a future vaccine. Less obvious and largely controversial is the impact of genetic diversity 
on disease progression, vertical transmission, response to antiretroviral therapy and drug-
resistance pathways.  
2. Viral variation 
High rates of genetic variation are a hallmark of retroviruses10. The molecular basis for 
variation is the error-prone nature of the reverse transcriptase enzyme and the absence of 
any exonucleolytic proof-reading mechanisms to correct the errors. The ability of HIV to 
generate extremely large numbers of diverse variants is an advantage to the virus in its 
continuous effort to adapt to local environments or respond to selection pressures. Viral 
variation in HIV is as a result of mutation and recombination. Due to the lack of proof-
reading ability of the HIV-1 reverse transcriptase enzyme, several mutations are generated. 
These point mutations are base-pair substitutions, and base-pair insertions or deletions. 
Recombination occurs frequently during reverse transcription, a consequence of having two 
RNA genomes packaged per virion11. 
A significant fraction of the HIV-1 group M global diversity includes interclade viral 
recombinants (Figure 1). These HIV-1 recombinants are found in geographic areas such as 
Africa, South America and Southeast Asia where multiple subtypes co-exist and account for 
10% of circulating HIV-1 strains. The HIV-1 recombinants are known as "circulating 
recombinant forms" or CRFs. Most HIV-1 recombinants have arisen from Africa and a 
majority contains segments originally derived from clade A viruses12.   
 
 
Fig. 1. Geographical distribution of HIV-1 subtypes (Adapted from WHO-UNAIDS HIV 
Vaccine Initiative) 
www.intechopen.com
 
The Changing Trends of HIV Subtypes and Its Implication on Mother-to-Child Transmission 
 
73 
In Thailand, for example, the predominant circulating strain consists of a clade A gag plus 
pol gene segment and a clade E env gene (CRF01_AE) 13. Within subtypes A and F, there are 
separate sub-clusters that are related closely to each other than to other subtypes. They are 
designated A1, A2 and F1, F2 respectively. Within subtypes B, C and G there are 
geographically localized sub-clusters that share a common ancestry as suggested in 
phylogenetic trees: subtype B from Thailand, subtype C from India and Ethiopia, and 
subtype G from Spain and Portugal. The classification of HIV strains into subtypes, sub-
subtypes and CRFs is a complex issue and the definitions are subject to change as new 
discoveries are made. These subtypes are generally confined to specific geographical regions 
with some of these subtypes having been characterized in Kenya. 
3. HIV-1 diversity in Kenya 
Kenya has about 2.2 million people living with HIV/AIDS. In 2003, the first national HIV 
prevalence survey was carried out, which estimated that 7% of adults aged 15-49 years in 
Kenya were infected14. Several studies on the HIV molecular epidemiology in Kenya has 
been done mostly based on partial sequencing of the env, gag or pol regions.  
In a study carried out between 1990 and 1992, 22 HIV-1-seropositive pregnant women and 1 
HIV-1-infected baby attending the Pumwani Maternity Hospital of Nairobi were studied as 
part of a cohort study of maternal risk factors in mother-to-child transmission. A 250-base 
pair (bp) fragment of the env gene encoding C2V3 was amplified mostly from 
Deoxyribonucleic Acid (DNA) isolated from primary peripheral blood mononuclear cells 
and subsequently sequenced. The results revealed that 19 were classified in subtype A 
versus 3 in subtype D, together with a much larger variation between subtype A strains as 
compared to subtype D strains, which suggested an earlier introduction of a subtype A 
strain, multiple introductions of subtype A strains, and/or faster diversification of subtype 
A strains as compared to subtype D strains 15. 
Another study carried out in 1996 revealed that 71% of the viruses were clade A and 29% 
were clade D. The most divergent clade A isolate identified in the study grouped closely 
with two other taxa previously reported as having no distinct clade affiliation16. These 
findings signaled the emergence of an outlier group of clade A variants or a new subtype of 
HIV-1. The first two virtually full-length genome sequences from HIV-1 subtype G were 
isolated in Sweden and Finland but originated in Congo and Kenya 17.  
In another study, HIV-1 subtype was determined among 320 women from Nairobi by a 
combination of heteroduplex mobility assays and sequence analyses of envelope genes, 
using geographically diverse subtype reference sequences as well as envelope sequences of 
known subtype from Kenya. The distribution of subtypes in this population was as follows: 
subtype A, 225 (70.3%); subtype D, 65 (20.5%); subtype C, 22 (6.9%); and subtype G, 1 (0.3%). 
Intersubtype recombinant envelope genes were detected in 2.2% of the sequences 
analyzed18. This study also addressed whether infection with a particular subtype is 
associated with differences in disease stage. It was found out that the plasma viral RNA 
levels were highest in women infected with subtype C virus, and women infected with 
subtype C virus had significantly lower CD4 lymphocyte levels than women infected with 
the other subtypes. 
To further define the genetic diversity of HIV-1 in Kenya, purified peripheral blood 
mononuclear cell DNA from 41 HIV-1 positive blood donations collected from six hospitals 
across southern Kenya was used to amplify near full-length genomes by nested PCR. 
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Among 41 near full-length genomes, 25 were non-recombinant (61%) and 16 were 
recombinant (39%). Of the 25 pure subtypes, 23 were subtype A, one was subtype C and one 
was subtype D. Most recombinants consisted of subtype A and either subtype C or subtype 
D; a few contained A2, a recently identified sub-subtype. Two A2/D recombinants had 
identical breakpoints and may represent a circulating recombinant form. A third A2/D 
recombinant had the same structure as a previously described Korean isolate, and these may 
constitute a second A2-containing circulating recombinant form19. The latter has been 
designated as CRF16. 
Our group further analyzed samples from pregnant women in rural western Kenya based 
on the envelope region (C2V3) and we identified for the first time the presence of CRF10 
which had been identified previously in Tanzania. The following were the other subtypes: 
20 subtype Al, 2 subtype D, 1 subtype C, 1 subtype G, 2A/D, 2A/C, and 2 were 
unclassified20. In order to investigate the in vivo evolution of recombinant HIV, we followed 
up on a mother who was initially co-infected with subtypes A and D in Kenya. Blood 
samples were obtained in 1996 and 2002, and HIV pol and env genes were amplified by PCR, 
cloned, sequenced, and phylogenetically analyzed. In this study, the clones (1996) generated 
from the pol and env genes clustered either with subtypes A and D reference strains. 
However, two clones from the pol gene were found to be independent recombinants 
between subtypes A and D by RIP analysis, suggesting active generation of recombinant 
forms. As for the 2002 sample, all the clones from the pol gene clustered only with the 
subtype A reference strain, while all the env clones clustered only with subtype D, denoting 
a dominance of an A/D recombinant form21. 
A detailed molecular epidemiological investigation on HIV-1-infected women attending an 
antenatal clinic in Kisumu, based on  gag-p24 region from 460 specimens revealed that 310 
(67.4%) were A, 94 (20.4%) were D, 28 (6.1%) were C, 9 (2.0%) were A2, 8 (1.7%) were G, and 
11 (2.4%) were unclassifiable. Analysis of the env -gp41 region revealed that 326 (70.9%) 
were A, 85 (18.5%) D, 26 (5.7%) C, 9 (2.0%) each of A2 and G, 4(0.9%) unclassifiable, and 1 
(0.2%) CRF02_AG. Parallel analyses of the gag-p24 and env-gp41 regions indicated that 344 
(74.8%) were concordant subtypes, while the remaining 116 (25.2%) were discordant 
subtypes. The most common discordant subtypes were D/A (40, 8.7%), A/D (27, 5.9%), 
C/A (11, 2.4%), and A/C (8, 1.7%) 22. 
In 2003/4, we carried out a study in northern Kenya, especially areas bordering Ethiopia, 
Sudan and Somalia to determine the circulating HIV-1 subtypes. This study revealed that 
50% were subtype A, 39% subtype C and 11% subtype D based on the analysis of partial env 
(C2V3) sequences23. This showed that subtype A and C are the dominant strains in 
circulation unlike the other regions with subtype A being dominant and followed by 
subtype D. We carried out a study in 2005 to establish HIV-1 subtype diversity among 
patients with sexually transmitted infections in Nairobi. In this study, 140 samples were 
collected and partial pol gene sequencing done. From the analysis it was established that 
subtype A1 was the major subtype (64%) followed by D (17%), C (9%), G (1%), and 
recombinants AD (4%), AC (3%), CRF02_AG (1%), and CRF16_A2D (1%) 24.  
From April 2005 to July 2006 we carried a study in North Rift to determine the subtypes 
circulating based on the pol region (RT). This was part of a study to explore the status of 
nevirapine resistant HIV genotypes in rural hospitals in North Rift Valley Province of 
Kenya. Of the  total of 39 HIV infected mother and child samples  successfully amplified and 
sequenced , 28 were subtype A1 (72 %), 5 subtype D (13%), 3 subtype C (8%), 1 subtype A2 
(3%) and one subtype G (3%).Our analysis shows that like other parts of the country the 
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predominant circulating subtype in North Rift was A125. This clearly shows that the HIV 
epidemic in Kenya is a dynamic one and is continually evolving. This observation is 
applicable to other countries where different subtypes are circulating. 
4. Antiretroviral therapy 
The development of antiretroviral therapy has been one of the most dramatic progressions 
in the history of medicine. The early years, 1987-90, brought great hope and the first modest 
advances using monotherapy26. The use of combination therapies became widely used in 
1996. Within only three years, from 1994-1997, the proportion of untreated patients in 
Europe decreased from 37% to 9%, whilst the proportion of highly active antiretroviral 
therapy (HAART) patients rose from 2% to 64%. Almost all compounds used as part of 
HAART are either nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), or protease inhibitors (PIs). These three classes of 
drugs target intracellular steps in the viral life cycle mediated by two viral enzymes, reverse 
transcriptase (RT) and HIV protease. The fusion inhibitors have been introduced recently 
and block the viral entry27,28.  
4.1 Reverse transcriptase inhibitors 
The reverse transcriptase inhibitors (RTI) are divided into nucleoside/nucleotide reverse 
transcriptase inhibitors (NRTI/NtRTI) and non-nucleoside reverse transcriptase inhibitors 
(NNRTI). The NRTI mimic the naturally occurring building blocks of DNA. After 
conversion to their triphosphate form, they compete with natural deoxynucleoside for 
binding to reverse transcriptase (RT), the necessary enzyme for HIV multiplication within 
the human cell. The NRTI also compete with deoxynucleoside triphosphates for 
incorporation into newly synthesized viral DNA chains, resulting in chain termination29. 
Seven compounds of the NRTI class have been approved by the US Food and Drug 
Administration (FDA): zidovudine (ZDV/AZT), stavudine (d4T), didanosine (ddI), zalcitabine 
(ddc), lamivudine (3TC), abacavir (ABC) and emtricitabine (FTC). The NRTI are divided into 
thymidines such as zidovudine (ZDV) and stavudine (d4T) which act preferentially on 
activated CD4 cells and non-thymidines such as didanosine (ddI), zalcitabine (ddc) and 
lamivudine (3TC) which act on resting and activated CD4 cells29. There is also a new class of 
anti-HIV drugs called nucleotide reverse transcriptase inhibitors which includes tenofovir. The 
concentration of NRTIs in cerebrospinal fluid (CSF) varies, but, thus far, zidovudine is the only 
drug with proven efficacy against the neurological complications of HIV30. 
The NNRTI target the reverse transcriptase enzyme. The NNRTI bind directly and non-
competitively to the enzyme at a position in close proximity to the substrate-binding site for 
nucleosides. The resulting complex blocks the catalyst-activated binding site of the reverse 
transcriptase, which can thus bind fewer nucleosides, and polymerization is slowed down 
significantly. These include efavirenz (EFZ), nevirapine (NVP) and delaviridine (DLV).  
4.2 Protease inhibitors 
The HIV protease cleaves the viral gag-pol polyprotein into its functional subunits. Inhibition of 
the protease, preventing proteolytic splicing and maturation, leads to the release of virus 
particles, which are non-infectious. Knowledge of the protease substrate and protease inhibitor 
structures has led to successful development of protease inhibitors31. The protease inhibitors 
(PI) work against HIV in the late stage of viral replication to prevent infectious virus 
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production from infected cells. They block the protease enzyme, which is necessary for the 
production of mature virions32. Seven compounds of the PI class have been approved by the 
US Food and Drug Administration (FDA): saquinavir (SQV), indinavir (IDV), ritonavir (RTV), 
nelfinavir (NFV), amprenavir (AMP), lopinavirritonavir (LPV), and atazanavir (ATV). 
4.3 Fusion inhibitors 
The fusion inhibitors block the attachment of the viral envelope to the cell membrane and 
the first to be approved was enfuvirtide (Fuzeon) by the US Food and Drug Administration 
(FDA) 33. The availability of these drugs has changed the treatment of HIV-1 infected 
patients. Escalating drug resistance in treatment-experienced HIV-1-infected patients has 
made management increasingly difficult. In clinical trials, tripanavir/enfuvirtide based 
salvage regimens have produced potent and durable responses34. Multiple observations in a 
variety of settings have demonstrated a decrease in mortality due to HIV related illnesses, 
and the incidence of HIV-1 related opportunistic infections has decreased35.  
However, the efficacy of these antiretroviral treatments is impaired by poor compliance 
with treatment regimens, sub-optimal antiviral potency and drug concentrations, and 
selection of drug-resistant HIV quasi species36, 37.  
5. Mechanisms of HIV drug resistance 
Human immunodeficiency virus replication is a highly dynamic process whereby large 
numbers of virions are created and destroyed by the immune system each day38. Mutations 
in the HIV genome are primarily generated during the initial steps of HIV replication cycle. 
The genomic ribonucleic acid (RNA) carried by HIV is copied into DNA early in the 
replication cycle. The RT makes spontaneous errors when copying the RNA, placing the 
incorrect nucleotide in the growing DNA strand about once in every 10,000 to 30,000 
nucleotides39. 
These nucleotide errors may cause changes in the amino-acid coding of the HIV proteins 
made from the HIV DNA, potentially altering the structure and/ or function of these 
proteins and affecting the replication competence of the viral strain. Since mutations in the 
proteins cause changes in drug susceptibility, the nomenclature for drug resistance 
mutations refers to the changes in the amino acid sequence of the proteins. Viral mutations 
are described in the format M184V, where the initial letter represents the wild-type amino-
acid of the particular protein, the number represents the mutated codon, or position of the 
protein and the end letter represents the mutant amino acid that is present40.  
In uncontrolled HIV infection, the high HIV replication rate generates a large pool of 
genetically but distinct HIV strains called quasispecies, each with potential to develop into 
the dominant strain. A strain possessing a mutation that provides a growth advantage in a 
particular environment such as in the presence of antiretroviral drugs out competes the 
other quasispecies and become the dominant viral strain in the population41.  
6. Mother-To-Child Transmission of HIV (MTCT) 
6.1 Pathogenesis of MTCT 
Human Immunodeficiency Virus can be transmitted from a HIV-infected mother to the 
infant during pregnancy (in utero), during delivery (intra partum) or via breastfeeding (post 
partum). The precise mechanisms responsible for in utero and intra partum MTCT remain 
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uncertain. The placenta is an effective barrier to infection, but conditions that compromise 
the placental unit such as vasoactive drug use or chorio-amnionitis, may allow mixture of 
maternal and foetal blood42. 
Virus in vaginal secretions, mother’s blood and breast milk may penetrate the infant’s 
mucosal tissues either during or after delivery. After penetrating the mucosal tissues, 
langerhans cells and key immune cells such as dendritic cells, macrophages and 
lymphocytes (CD4 T cells) take up the virus. These cells transport the virus to the lymph 
nodes where it replicates. In 5-7 days post exposure, HIV appears in the blood within 
infected CD4 T cells or as free virions43.  
6.2 Risk factors for MTCT 
In non-breastfed populations, 25-30% of infected infants have detectable provirus in their 
peripheral blood lymphocytes at birth, suggesting in utero infection44. The detection of HIV 
RNA or provirus after a week or two suggests intra partum transmision of HIV-1. In 
breastfed populations, approximately 15% of infections are thought to occur in utero, 65-70% 
during delivery, and 15-20% during post partum through breastfeeding45.   
Maternal plasma HIV-1 viral load is one of the strongest predictors of MTCT46. Mother-to-
child transmission of HIV can occur at any maternal viral load, but the risk of transmission 
increases with increasing maternal plasma HIV-1 load. Mothers with a high viral load 
during pregnancy are more likely to transmit virus to their infants during the in utero or 
intra partum periods, particularly if they seroconvert while pregnant47. Prolonged labour 
accounts for MTCT during delivery. An increased risk of MTCT has been observed in first-
born twins48. In addition, cervico-vaginal ulcers or high maternal cervical or vaginal HIV-1 
proviral copy numbers have been significantly associated with MTCT, independent of 
maternal plasma HIV-1 load49.  
Available data suggests that most breast milk transmission occurs within the first months of life. 
Longer durations of breastfeeding are associated with increased risk of HIV-1 transmission to 
infants50. The maternal factors associated with breastfeeding transmission include younger age 
and higher parity, maternal HIV disease stage and breast health. Advanced disease stage is a risk 
factor associated with postnatal transmission of HIV-1. This is associated with low blood CD4+ 
cell counts and higher maternal peripheral blood or milk viral load51, 52.  
Several studies have established the association between transmission of HIV-1 through 
breastfeeding with maternal breast abnormalities such as breast abscesses, mastitis and 
nipple lesions. In Kenya, for example, mastitis and breast abscesses were associated with 
late postnatal transmission of HIV-153. In Malawi, women with increased milk sodium 
concentrations consistent with subclinical mastitis had higher milk viral load47. In another 
study in Kenya, maternal nipple lesions and mastitis were associated with increased risk of 
postnatal transmission. Oral candidiasis in infants before 6 months of age was associated 
with postnatal transmission54. A study in the Ivory Coast suggested maternal breast 
abscesses, cracked nipples and oral candidiasis in infants as risk factors for late postnatal 
transmission of HIV-1 through breastfeeding55.  
7. Strategies for reduction of MTCT 
7.1 Behavioural Intervention 
Counselling and testing in the antenatal clinic offers an opportune time to discuss 
prevention of primary HIV infection. For women who are found to be HIV-negative, safe 
sexual behaviour should be reinforced.  
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7.2 Nutritional intervention 
Low Vitamin A levels have been associated with higher rates of MTCT and with higher 
levels of virus in breast milk56. Among HIV-infected pregnant women, low selenium status 
increases risk of MTCT and poor pregnancy outcomes57. Therefore, HIV positive pregnant 
women should maintain adequate nutritional status. 
7.3 Obstetric intervention 
Studies have shown that vaginal cleansing with antiseptic is associated with reduced MTCT 
and improved perinatal outcome58. The other obstetric intervention is elective caesarean 
section (CS). Prospective cohort studies have shown that the rate of perinatal transmission 
among women undergoing elective CS delivery was significantly lower than among women 
undergoing non-elective CS or vaginal delivery59.  
7.4 Antiretroviral prophylaxis 
The use of antiretroviral prophylactic therapies to reduce MTCT came into effect following 
studies by Paediatrics AIDS Clinical Trial Group 07660. In this trial, zidovudine (ZDV) was 
given to mothers beginning at 14-34 weeks of pregnancy, intravenously during labour and 
for 6 weeks to infants. This resulted in 68% reduction in MTCT. Owing to the high cost and 
complexity of the regimen, recommendations were made for shorter and simplified forms to 
be tried in developing countries. A trial in Thailand showed a 50% reduction in mother-to-
child transmission of HIV in non-breastfeeding women who took an exclusive oral ZDV 
regimen twice a day beginning at 36 weeks gestation and every 3 hours during labour61.  
An identical regimen on breastfeeding populations in two areas of West Africa showed high 
efficacy rates by 3-6 months62, 63. In the perinatal transmission trial (PETRA®) carried out in 
Eastern and Southern African countries, a combination of zidovudine and lamivudine had 
efficacies beyond 65% at 18 months64. In Kenya, a study was carried out to determine the 
feasibility of using short-course zidovudine to prevent MTCT in a breastfeeding population in 
a rural area. The mothers were given a daily dose of 400 mg of ZDV starting at 36 weeks of 
gestation and another 300 mg every three hours intra partum. No ZDV was administered to 
infants after delivery. Even though not all the mothers took ZDV, the HIV vertical 
transmission rate was reduced by 65.6% 65. In the ultra-short nevirapine (NVP) HIVNET 012® 
trial in Uganda, one dose given to the mother during labour combined with one dose given to 
the neonate within 72 hours of birth reduced 3-month transmission by 47% 66.  These studies 
have formed the basis of recommendations on the use of short course antiretroviral therapies 
for prevention of mother-to-child transmission of HIV in developing countries45, 67.  
8. Drug resistance, viral subtypes and implications on MTCT 
Drug resistance is one of the greatest threats to successful long-term antiretroviral therapy 
(ART). Combination ART delays the onset of drug resistance, but drug resistance can still 
develop and lead to a reduction in drug efficacy. Once resistance has developed to a drug or 
drug class, resistant viruses are archived in lymphoid tissue, and responses to the drug or 
drug class are compromised indefinitely68.  Because cross-resistance may also limit the efficacy 
of unused ART agents, many persons infected with HIV can exhaust effective ART treatment 
options quickly if careful selection and monitoring of initial ART are not undertaken. 
Many studies have shown the existence of polymorphisms among non-B strains, especially 
naturally occurring minor mutations in the protease gene, as well as atypical substitutions in 
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protease (PR) and reverse transcriptase (RT) at positions associated with resistance69. 
Accessory (or minor) mutations may not result in a significant decrease in susceptibility70, 
but  may be associated with an increase in viral fitness (replication capacity) and/or increase 
in resistance level associated with major mutations, and thus long-term failure of therapy. It 
is not clear whether differences exist among the various forms of HIV-1 (groups, subtypes, 
and CRFs) in terms of transmissibility, pathogenicity, and responses to antiretroviral 
therapy, but some in vitro and in vivo observations suggest that certain variants may respond 
differently to certain antiretroviral drugs71.  
There is a solid body of evidence to indicate that drug resistance pathways vary between 
different subtypes. One classic example is that of the development of NFV resistance in 
subtypes B and G. Patients with subtype B tend to preferentially develop the D30N mutation, 
whereas those with other subtypes including G tend to preferentially develop L90M. Even in 
cases where the first mutation is L90M in both B and G subtypes, subsequent mutations differ 
significantly. In subtype B, L63P is the second mutation and occurs in almost 100% of cases, 
suggesting that the progression of resistance is dependent on the emergence of this mutation, 
followed by the selection of V77I and other mutations. In subtype G, L89I follows the 
emergence of L90M, and is present in almost 100% of cases suggesting a role in subtype G 
similar to that of L63P in subtype B. The third mutation can be either A71V or I54V72, 73.  
The HIV-1 group O and HIV-2 strains are naturally resistant to non-nucleoside reverse 
transcriptase inhibitors (NNRTIs). Human immunodeficiency virus type 2 variants carry the 
major NNRTI resistance mutations, Y181I, Y188L, and G190A, in addition to the minor 
mutations, K101A, V106I, and V179I. Human immunodeficiency virus type 2 isolates show 
1000–10,000-fold resistance to first and second-generation NNRTIs. These observations 
clearly shows that the use of NNRT’s to reduce the transmission rates of mother-to-child 
will not work among women infected with HIV-2. Subtype O viruses show resistance to 
NNRTIs through two distinct mutational profiles involving the NNRTI secondary 
mutations, A98G, K103R, and I79E, in the presence or absence of Y181C. Subtype O viruses 
without Y181C show greater than 100-fold and greater than 500-fold resistance to nevirapine 
and efavirenz, respectively74. 
Clinical trials demonstrate a disparity in the frequency of primary nevirapine resistance, 
involving K103N or Y181C in 65–69, 36, 19 and 21% in women with subtype C, D, A and 
CRF02_AG infections, respectively75,76,77,78. Subtype C viruses have a signature valine codon 
polymorphism absent in other non-B subtypes. This subtype C polymorphism facilitates the 
acquisition of V106M upon selective drug pressure with efavirenz but not nevirapine. The 
V106M confers cross-resistance to NNRTIs79.  
A rapid selection of K65R is observed in subtype C strains compared with the slow 
evolution of K65R in subtype B80. Subtype G strains are less susceptible in vitro to protease 
inhibitors (PIs), the rate of occurrence of nevirapine resistance-associated mutations after a 
single dose is significantly higher in women with HIV-1 subtype C than in women with 
subtype A or D81, 82.  
Nevirapine prophylaxis used in the HIVNET 012 66 has been reported to result in selection 
of single point mutations strongly associated with high resistance to non-nucleoside reverse 
transcriptase inhibitors that were detectable in 19% of the mothers and 46% of the infants83. 
By contrast with HIVNET 012®, where intra partum and neonatal exposure to nevirapine or 
zidovudine was limited, the PETRA® interventions led to ongoing maternal exposure to 
zidovudine plus lamivudine from 36 weeks gestation. It has been postulated that induction 
of significant single mutation (M184V) lamivudine resistance will occur84.  
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Viral genetic diversity seems to have an important role on MTCT and in timing of 
transmission. In a study by Kwiek and colleagues, among HIV-1 subtype C infected 
mothers, they observed different diversity patterns during intrauterine and intrapartum 
transmissions. Intrauterine infected-infants tended to be infected by one single variant that 
was more detected in the mother’s plasma, whereas intrapartum infected-infants showed 
multiple variants of detected and undetected variants of the mother’s quasispecies. 
Regardless of the time of transmission, nearly 50% of the quasispecies included the 
transmission of variants that were not detected in the mother’s blood plasma, suggesting a 
genetic bottleneck and arguing against a stochastic model of vertical transmission85. 
A number of studies have been carried out to determine the role of HIV-1 subtypes on 
MTCT. A study carried out in Kenya among 414 women, MTCT rates were higher among 
women with subtype D compared with subtype A in either the gp4186. Such differences may 
be caused by altered cellular tropism for placental cell types. However, a study carried out 
in Uganda found no significant difference in the rate of MTCT in women with subtype A 
versus D87. Several HIV-1 structural, regulatory and accessory genes are highly conserved 
following MTCT. In addition, HIV-1 sequences from non-transmitting mothers are less 
heterogeneous compared with transmitting mothers, suggesting that a higher level of viral 
heterogeneity influences MTCT. 
The mechanism through which MTCT occurs seems not to be fully clear, and should be a focus 
point for researches to understand the biology of viral transmission and also attempt to 
eliminate one of transmission routes. Further studies are needed regarding the mechanisms 
that determine the moment of transmission, and the influence of the viral subtype, the 
influence of host immunity, recombination and drug resistance on MTCT may provide insight 
into new prevention strategies and the development of an effective vaccine88. Early and 
universal access to ARV during pregnancy is the most important measure to achieve a 
decrease in vertical transmission in areas where clade distribution differs89. 
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